BCL2 and cancer: Hence, targeting the interactions of VDAC1 with anti‐apoptotic proteins (Bcl‐2, Bcl‐xL) or proteins supporting the metabolic requirements of cancer cells (HK‐I, HK‐II) is a promising strategy for the development of anticancer agents.